ACC CardiaCast: Mechanisms of Action for the Newly Approved Cardiac Myosin Inhibitor Recently Approved for HCM
ACC CardiaCast - Podcast autorstwa American College of Cardiology - Piątki
In this episode, Drs. Matt Martinez and Ahmad Masri discuss the recent approval by the FDA of the cardiac myosin inhibitor Mavacamten for the treatment of hypertrophic cardiomyopathy, and mechanisms of action.
